Vaccine maker to seek approval for jab as it tries to diversify product pipeline
US decision hands biotech group its first regulatory blessing since its blockbuster Covid-19 jab
Funding would help to bolster stockpile as CDC reports third dairy worker infected
Fears of growing outbreak drive revival in vaccine group stocks which have been out of favour since pandemic ended
Decision is a boon for the mRNA-vaccine maker in its legal fight to recoup pandemic profits from rivals
Moderna alleges Pfizer and BioNTech infringed its patents in use of mRNA platform
Pledges to invest in pandemic preparedness with facility in Kenya fall short as sales of Covid jabs decline
US biotech company’s stock worth nearly $500 at its peak in August 2021, currently trades at less than $87
Case studies in best practice among general counsel and company legal teams in North America
Biotech blames weaker US sales after lowering full-year forecast
Combined jab as effective as separate shots in early stage tests
Companies have yet to provide investors with convincing post-pandemic strategies
Brussels launches talks for mRNA jabs to augment existing contract with BioNTech/Pfizer
Despite progress on a flu jab, the biotech group will be lossmaking for the next three years
Trial finds latest version elicited better immune response than existing jabs
Drug regulator’s decision is the first step towards a new round of jabs as cases rise in the US
Prominent figure in UK pandemic response becomes medical consultant at pharma group
Medicines produced by pharma group will be for domestic use only
Noubar Afeyan says court rulings on abortion pills and access to healthcare undermine efforts to combat diseases
Covid vaccine maker is sitting on $18bn and embarking on a host of ambitious projects
Four member states including Poland say amended deal is not ‘fair solution’ to surplus of shots
Success in battle against Covid does not ensure success against tumours, but should narrow the odds
Study suggests combination with Merck immunotherapy drug reduces risk of death in high-risk patients
Ending of pharma group’s IP truce spells fight for future of mRNA technology
UK Edition
